secwatch.observer — SEC 8-K summary
======================================

Issuer:     Akebia Therapeutics, Inc. (AKBA)
CIK:        0001517022
Form:       8-K
Filed at:   2022-12-28T23:59:59+00:00
Accession:  0001193125-22-313116
Event type: other_material
Sentiment:  negative
Materiality: 0.75
Item codes: 1.01, 1.02, 2.05
LLM model:  deepseek-v4-flash:cloud@v2

Akebia licenses ferric citrate to Averoa for EU/UK; terminates BioVectra supply deal for $32.5M
--------------------------------------------------------------------------------

- Granted Averoa exclusive license to develop/commercialize ferric citrate in EEA, Turkey, Switzerland, UK; royalties mid-single to low double digit.
- Terminated BioVectra manufacturing/supply agreements for Auryxia (ferric citrate) effective immediately for business reasons.
- Company to pay BioVectra $32.5M: $17.5M upfront plus six quarterly $2.5M payments commencing April 2024.
- Mutual release of all claims under terminated agreements; company retains supply obligation to Averoa under new contract.
- Akebia may terminate supply agreement with Averoa on 24-month notice after January 1, 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1517022/000119312522313116/0001193125-22-313116-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1517022/000119312522313116/d418020d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-313116

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer